Pomerantz Law Firm Investigates Sionna Therapeutics for Potential Securities Fraud
The law firm of Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Sionna Therapeutics, Inc. (NASDAQ: SION) and certain officers or directors on behalf of investors. The investigation follows a significant drop in the company's stock price after it announced that its Phase 2a trial for SION-719 failed to meet key endpoints when used alongside Trikafta. On August 10, 2026, Sionna released top-line data from two clinical programs. The failure of the PreciSION CF trial led to a sharp decline in its stock price—dropping $46.54 per share (91.18%) to close at $4.50 on that day. Pomerantz LLP, known for leading class action litigation cases involving corporate misconduct and securities fraud, is seeking investors who may wish to join a potential class-action lawsuit.
Tickers: $SION
Topics: clinical trial results securities fraud stock price drop